Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
“AS's going isn't good news at all. Surely he would be staying if all was going to plan?“
Completely disagree, AS’s position had become untenable due to his many (and well talked about here) failings.
Keeping him on in any capacity would be the easy/ weak thing to do. That’s the game as CEO. He will have been extremely well compensated I’m sure.
Onwards and upwards!
For those that were worried by the toned down wording in previous comms - the words “Holy Grail” have made a reappearance ….
Looks like things haven’t gone belly up after all and the team are at just as confident about what we have here.
Based on this very favourable three-weekly dosing safety profile, Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.
Touk, were they definitely accepted?
I put a request in via HL yesterday and think they just go into a pending state for now (or at least mine have).
The wording on the offer message as follows;
“What happens after I apply?
If you apply for shares you will receive two further secure messages. The first will confirm your application and be sent shortly after 11am on Monday 04 March. The second will confirm how many shares you have been allocated and will be sent once the results have been announced.”
I guess the issue here is that their report is largely based on the information that was presented to us by AS, at the time “Paradigm shifts” and “financing, don’t worry about that” comments were made.
The question is - Can we trust anything that’s been said? I genuinely hope so, as I have a (large to me) investment here and have also requested 20% more in the placement, but it was an extremely tough call. To mis-quote the phrase “in for a pound, in for a penny” and all that …